bisphosphonate-associated osteonecrosis of the jaw/背部痛

The convenience of (18)F-fluoride imaging is undeniable both because of its favorable tracer and because of its technical characteristics, including high image quality and short examination times leading to increased patient comfort. Depending on the activity administered, the radiation dose to

Minodronate is a third-generation bisphosphonate that was developed and approved for clinical use in osteoporosis therapy in Japan. The mechanism of action for suppressing bone resorption is the inhibition of farnesyl pyrophosphate synthase, a key enzyme in the mevalonic acid metabolic pathway of

(18)F-sodium fluoride (NaF) as an imaging tracer portrays calcium metabolic activity either in the osseous structures or in soft tissue. Currently, clinical use of NaF-PET is confined to detecting metastasis to the bone, but this approach reveals indirect evidence for disease activity and will have